<BJCT... Investing In A Concept.>
You got the right sector Jim, ah hah. Bios are hot, and this Co. has
an interesting product. BJCT's product has the obvious benefit of eliminating the risk of contaminated needles. Great, but there appears to be more going on here.
According to Yahoo, there was an analyst covering this co. with a Strong Buy rating, but no analyst follows the stock at this time. Don't know who the analyst was, but I hope it wasn't H & Q, because they own a bunch of the shares. Anyway, Dick Davis Journal picked up the stock earlier this month (MAY). Hmmmmmm...I think I know why?
The company put itself on the line last year with their joint venture with ELAN with the intent of bringing a commercially viable blood glucose monitoring system to market. They seem to have all their eggs in the glucose monitoring product. No mentions can be found on their 10q or 10k of their arrangement with Hoffman Laroche to produce a non-needle injection system. Furthermore, their new CFO cut the sales force. Looks like a change in strategy. The Co. is counting on their relationships and it looks like some new relationships are forthcoming.
Illionois set up Crisis Prepardness Centers earlier this year and they included BJCT's injection system in their inventory. President Clinton has announced his intention of major funding for Crisis Prepardness Centers throughout the country. Sooner or later we're going to get some kind of bio attack and the nation should be ready. This could have a huge impact on BJCT.
So, what's to like about this stock are the implications of Clinton's prepardness policy, the Elan JV and let's throw in the one insider who has been buying up 28,000 shares at prices from 1.24 to 2.01
over the prior two months.
I would like to know who the analyst that dropped coverage is and why and what's going on with the Hoffman LaRoche deal. Very interisting Jim.
Sergio |
